You need to sign in or sign up before continuing.
The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
The development of neutralizing anti-factor VIII alloantibodies (inhibitors) in patients with severe hemophilia A may depend on the concentrate used for replacement therapy. ⋯ Patients treated with plasma-derived factor VIII containing von Willebrand factor had a lower incidence of inhibitors than those treated with recombinant factor VIII. (Funded by the Angelo Bianchi Bonomi Foundation and others; ClinicalTrials.gov number, NCT01064284; EudraCT number, 2009-011186-88.).